Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019

January 2019 | 60 pages | ID: F1F8A0D2DFFEN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

INTRODUCTION

DelveInsight's, “Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019' report provides comprehensive insights about marketed and Phase III products for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease). The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)

Coverage of API manufacturers for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)

This report provides a comprehensive understanding of the emerging Phase III therapies for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.

METHODOLOGY

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

SCOPE

• A review of the marketed products for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details.
• Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
• API manufacturers for the marketed products with location details
• 
  Emerging Phase III product profiles for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) including product description, developmental activities, licensors & collaborators and chemical information

REASONS TO BUY

• API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
• Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
• Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Contents

1. REPORT INTRODUCTION

2. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE): OVERVIEW

Risk Factors
Causes
Symptoms
Pathophysiology
Prognosis
Diagnosis
Treatment

3. COMPARATIVE ANALYSIS OF MARKETED AND EMERGING PRODUCTS

4. MARKETED THERAPIES

4.1. Drug 1: Company name
Product Description
Route of Synthesis
Mechanism of Action
Pharmacology
Pharmacodynamics
Pharmacokinetics
Adverse Reactions
Clinical Trials
Regulatory Milestones
Product Development Activities
  4.1.1 Product Details
United States
Europe
  4.1.2 Global Sales Assessment
Historical Global Sales
Forecasted Global Sales
  4.1.3 Patent Details
Other marketed products in the detailed report

5. EMERGING THERAPIES (PHASE III)

5.1 Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
  5.1.1 Forecasted Global Sales
Other Phase III profiles in the detailed report

APPENDIX

Methodology
Consulting Services
About DelveInsight
Contact Us

List Of Tables

LIST OF TABLES

Table 1: List of Marketed and Emerging Products
Table 2: Drug Product Details, United States
Table 3: Drug Product Details, Europe
Table 4: Drug, Historical Global Sales till 2018 (in million USD)
Table 5: Drug, Forecasted Global Sales from 2019-2021 (in million USD)
Table 6: API Manufacturers Region wise
Table 7: API Manufacturers for United States
Table 8: API Manufacturers for Europe
Table 9: API Manufacturers for China
Table 10: API Manufacturers for India
Table 11: Patent Details
Table 12: Emerging Therapies (Phase III)
Table 13: Drug, Forecasted Global Sales from 2019-2021 (in million USD)

List Of Figures

LIST OF FIGURES

Figure 1: Comparative Analysis of Marketed and Emerging Products
Figure 2: Drug, Historical Global Sales till 2018 (in million USD)
Figure 3: Drug, Forecasted Global Sales from 2019-2021 (in million USD)
Figure 4: Patent Details
Figure 5: API Manufacturers Region wise
Figure 6: Drug, Forecasted Global Sales from 2019-2021 (in million USD)